[
  {
    "ts": "2025-11-07T03:21:17+00:00",
    "headline": "Jim Cramer Says Pfizer “Will Continue to Sell at Eight Times Earnings”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-says-pfizer-continue-032117950.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "95bbdb6e-f6c6-3f90-88f0-a6ea628e082a",
      "content": {
        "id": "95bbdb6e-f6c6-3f90-88f0-a6ea628e082a",
        "contentType": "STORY",
        "title": "Jim Cramer Says Pfizer “Will Continue to Sell at Eight Times Earnings”",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a […]",
        "pubDate": "2025-11-07T03:21:17Z",
        "displayTime": "2025-11-07T03:21:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c",
          "originalWidth": 1920,
          "originalHeight": 1272,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lBNvOkwEcDTC6JSi8u6u5Q--~B/aD0xMjcyO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 1920,
              "height": 1272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l4R272WQ4gg_U7DbC5QzrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-pfizer-continue-032117950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-pfizer-continue-032117950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T10:30:00+00:00",
    "headline": "This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed.",
    "summary": "The founders of Metsera have a battle to buy their company. It would be their second time striking deal gold.",
    "url": "https://www.wsj.com/health/pharma/metsera-pfizer-bid-weight-loss-drugs-e95dadcc?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "04f80ce8-0931-3b97-9f3c-4de6cb72d189",
      "content": {
        "id": "04f80ce8-0931-3b97-9f3c-4de6cb72d189",
        "contentType": "STORY",
        "title": "This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed.",
        "description": "",
        "summary": "The founders of Metsera have a battle to buy their company. It would be their second time striking deal gold.",
        "pubDate": "2025-11-07T10:30:00Z",
        "displayTime": "2025-11-07T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/04f80ce8-0931-3b97-9f3c-4de6cb72d189/this-unlikely-duo-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6733447ed0f1fbe1f832faffd6c0e15d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iMbL84xpcQXGNaDasIdrsA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6733447ed0f1fbe1f832faffd6c0e15d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DKP9j8iYwslqMrh5vgFjtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6733447ed0f1fbe1f832faffd6c0e15d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/metsera-pfizer-bid-weight-loss-drugs-e95dadcc?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVN.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:20:40+00:00",
    "headline": "Elon Musk pay deal, AI bubble worries and pharma wars",
    "summary": "Elon Musk's targets in order to hit his $1 trillion pay package are aggressive according to Tesla's (TSLA) board. Chris Rossbach from J.Stern agrees. This week concerns over an AI bubble have grown and shares of Nvidia (NVDA), Palantir (PLTR) and AMD (AMD) have faltered. The battle to buy Metsera (MTSR) is intensifying as both Novo Nordisk (NVO, NOVO-B.CO) and Pfizer (PFE) make bids for the obesity drug developer this week.",
    "url": "https://finance.yahoo.com/video/elon-musk-pay-deal-ai-132040099.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "a73e8505-b61a-3357-9b68-9dd5c9f41f0a",
      "content": {
        "id": "a73e8505-b61a-3357-9b68-9dd5c9f41f0a",
        "contentType": "VIDEO",
        "title": "Elon Musk pay deal, AI bubble worries and pharma wars",
        "description": "<p>Elon Musk's targets in order to hit his $1 trillion pay package are aggressive according to Tesla's (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/TSLA\">TSLA</a>) board. Chris Rossbach from J.Stern agrees. This week concerns over an AI bubble have grown and shares of Nvidia (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/NVDA\">NVDA</a>), Palantir (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/PLTR\">PLTR</a>) and AMD (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/AMD\">AMD</a>) have faltered. The battle to buy Metsera (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/MTSR\">MTSR</a>) is intensifying as both Novo Nordisk (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>, <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/quote/NOVO-B.CO\">NOVO-B.CO</a>) and Pfizer (<a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>) make bids for the obesity drug developer this week.</p>",
        "summary": "Elon Musk's targets in order to hit his $1 trillion pay package are aggressive according to Tesla's (TSLA) board. Chris Rossbach from J.Stern agrees. This week concerns over an AI bubble have grown and shares of Nvidia (NVDA), Palantir (PLTR) and AMD (AMD) have faltered. The battle to buy Metsera (MTSR) is intensifying as both Novo Nordisk (NVO, NOVO-B.CO) and Pfizer (PFE) make bids for the obesity drug developer this week.",
        "pubDate": "2025-11-07T13:20:40Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/2e1aa1c0-bbd9-11f0-ab87-947f812bc14a",
          "originalWidth": 5500,
          "originalHeight": 3097,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZDiclwaHjYCNr53xrS2.uQ--~B/aD0zMDk3O3c9NTUwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/2e1aa1c0-bbd9-11f0-ab87-947f812bc14a.cf.webp",
              "width": 5500,
              "height": 3097,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kcIoXJztPCR9MZtIv.XsyA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/2e1aa1c0-bbd9-11f0-ab87-947f812bc14a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/elon-musk-pay-deal-ai-132040099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/elon-musk-pay-deal-ai-132040099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:16:14+00:00",
    "headline": "Earnings live: Block stock drops after earnings miss, Airbnb pops, Opendoor pitches turnaround plan",
    "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finance.yahoo.com/news/live/earnings-live-block-stock-drops-after-earnings-miss-airbnb-pops-opendoor-pitches-turnaround-plan-131614884.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "035a1404-14a9-4292-96b8-08cca27526ee",
      "content": {
        "id": "035a1404-14a9-4292-96b8-08cca27526ee",
        "contentType": "STORY",
        "title": "Earnings live: Block stock drops after earnings miss, Airbnb pops, Opendoor pitches turnaround plan",
        "description": "",
        "summary": "Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
        "pubDate": "2025-11-07T13:16:14Z",
        "displayTime": "2025-11-07T14:04:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2021-08/e9a7d4d0-f347-11eb-81ef-0815aa9d257f",
          "originalWidth": 4196,
          "originalHeight": 2797,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8rb9gAReJXiDmzBnizQGTQ--~B/aD0yNzk3O3c9NDE5NjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2021-08/e9a7d4d0-f347-11eb-81ef-0815aa9d257f.cf.webp",
              "width": 4196,
              "height": 2797,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bcdT60p9sr2yXiQZfTIb.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2021-08/e9a7d4d0-f347-11eb-81ef-0815aa9d257f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-block-stock-drops-after-earnings-miss-airbnb-pops-opendoor-pitches-turnaround-plan-131614884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/live/earnings-live-block-stock-drops-after-earnings-miss-airbnb-pops-opendoor-pitches-turnaround-plan-131614884.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "DUOL"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "ABNB"
            },
            {
              "symbol": "OPEN"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "SMCI"
            },
            {
              "symbol": "UBER"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "QCOM"
            },
            {
              "symbol": "ARM"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MCD"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "HOOD"
            },
            {
              "symbol": "DASH"
            },
            {
              "symbol": "SNAP"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "CEG"
            },
            {
              "symbol": "MAR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:13:25+00:00",
    "headline": "Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera",
    "summary": "Pharma rivals fight for control of next-generation obesity drug maker",
    "url": "https://finance.yahoo.com/news/pfizer-novo-nordisk-face-off-131325522.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "b0d2ea74-93d3-36b9-852b-e641b9f775f6",
      "content": {
        "id": "b0d2ea74-93d3-36b9-852b-e641b9f775f6",
        "contentType": "STORY",
        "title": "Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera",
        "description": "",
        "summary": "Pharma rivals fight for control of next-generation obesity drug maker",
        "pubDate": "2025-11-07T13:13:25Z",
        "displayTime": "2025-11-07T13:13:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vu.kxzmN7yCA.wz8Cs.cHg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Brb0J12XOUXl4lathAg3vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-novo-nordisk-face-off-131325522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-novo-nordisk-face-off-131325522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:00:03+00:00",
    "headline": "The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.",
    "summary": "Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?",
    "url": "https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f7b1bb3f-913e-3ed2-b14a-a511102acf42",
      "content": {
        "id": "f7b1bb3f-913e-3ed2-b14a-a511102acf42",
        "contentType": "STORY",
        "title": "The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.",
        "description": "",
        "summary": "Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?",
        "pubDate": "2025-11-07T13:00:03Z",
        "displayTime": "2025-11-07T13:00:03Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7b1bb3f-913e-3ed2-b14a-a511102acf42/the-weight-loss-drugs-craze.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/6957882acf125f3e690d774d013e61af",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TmIuGINDJ4jw.ePvaRQ6LA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6957882acf125f3e690d774d013e61af.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y0YPyPni.dhRliRbMw0.7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/6957882acf125f3e690d774d013e61af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T12:40:00+00:00",
    "headline": "Premenstrual Syndrome (PMS) Treatment Market: Global Industry Outlook with Company Analysis Report 2025-2033",
    "summary": "Factors like healthcare access, urbanization, and innovation, particularly in the U.S., France, and China, propel market expansion. Key players such as Pfizer, Bayer, and GlaxoSmithKline are fostering advancements in PMS therapies. Premenstrual Syndrome Treatment Market Premenstrual Syndrome Treatment Market Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The \"Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, Countries and Company Analysis 2025-2033\" has been adde",
    "url": "https://finance.yahoo.com/news/premenstrual-syndrome-pms-treatment-market-124000683.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "276aa7bc-aad5-3ce3-8a8c-693a3ba56153",
      "content": {
        "id": "276aa7bc-aad5-3ce3-8a8c-693a3ba56153",
        "contentType": "STORY",
        "title": "Premenstrual Syndrome (PMS) Treatment Market: Global Industry Outlook with Company Analysis Report 2025-2033",
        "description": "",
        "summary": "Factors like healthcare access, urbanization, and innovation, particularly in the U.S., France, and China, propel market expansion. Key players such as Pfizer, Bayer, and GlaxoSmithKline are fostering advancements in PMS therapies. Premenstrual Syndrome Treatment Market Premenstrual Syndrome Treatment Market Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The \"Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, Countries and Company Analysis 2025-2033\" has been adde",
        "pubDate": "2025-11-07T12:40:00Z",
        "displayTime": "2025-11-07T12:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/294c9a5035f68d8849b6609e6b0c3ca1",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Premenstrual Syndrome Treatment Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rsDrtTKGEJiG0d0QTYLyzw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/294c9a5035f68d8849b6609e6b0c3ca1.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9VX2Rrfop.Ah7Q0x8vUH6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/294c9a5035f68d8849b6609e6b0c3ca1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/premenstrual-syndrome-pms-treatment-market-124000683.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/premenstrual-syndrome-pms-treatment-market-124000683.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "GSK.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T16:11:04+00:00",
    "headline": "“Pfizer (PFE) Beat The Numbers And People Just Yawned,” Says Jim Cramer",
    "summary": "We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE) reported its third-quarter earnings report yesterday. The results were a solid bunch of numbers that saw the firm post $16.65 billion in revenue and $0.87 in adjusted […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-beat-numbers-people-161104004.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "e020c7be-e86c-397d-82eb-3580886a37bb",
      "content": {
        "id": "e020c7be-e86c-397d-82eb-3580886a37bb",
        "contentType": "STORY",
        "title": "“Pfizer (PFE) Beat The Numbers And People Just Yawned,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE) reported its third-quarter earnings report yesterday. The results were a solid bunch of numbers that saw the firm post $16.65 billion in revenue and $0.87 in adjusted […]",
        "pubDate": "2025-11-07T16:11:04Z",
        "displayTime": "2025-11-07T16:11:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/e07100855b9769c67c145e877d715493",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "\"Pfizer (PFE) Beat The Numbers And People Just Yawned,\" Says Jim Cramer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JdsUG2H00H23uAd7a0c6qw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/e07100855b9769c67c145e877d715493.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QqxTp0yGkKMLrei39SQnQQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/e07100855b9769c67c145e877d715493.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-beat-numbers-people-161104004.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-beat-numbers-people-161104004.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T15:22:57+00:00",
    "headline": "Does Pfizer’s Recent Share Price Rebound Signal a New Opportunity in 2025?",
    "summary": "Ever wondered if Pfizer is a hidden gem or just treading water in today’s market? Let’s jump in and get to the bottom of whether the stock is truly worth your attention right now. Pfizer’s share price ticked up 2.3% this week, but has still slipped 5.4% in the last month and is down 6.6% year to date, with a modest 1.4% slide over the last year. Market watchers have been parsing several big headlines recently, including the company’s status as a leader in transformational therapies and some...",
    "url": "https://finance.yahoo.com/news/does-pfizer-recent-share-price-152257915.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e57307b7-3935-3f35-b849-963e006a995f",
      "content": {
        "id": "e57307b7-3935-3f35-b849-963e006a995f",
        "contentType": "STORY",
        "title": "Does Pfizer’s Recent Share Price Rebound Signal a New Opportunity in 2025?",
        "description": "",
        "summary": "Ever wondered if Pfizer is a hidden gem or just treading water in today’s market? Let’s jump in and get to the bottom of whether the stock is truly worth your attention right now. Pfizer’s share price ticked up 2.3% this week, but has still slipped 5.4% in the last month and is down 6.6% year to date, with a modest 1.4% slide over the last year. Market watchers have been parsing several big headlines recently, including the company’s status as a leader in transformational therapies and some...",
        "pubDate": "2025-11-07T15:22:57Z",
        "displayTime": "2025-11-07T15:22:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-pfizer-recent-share-price-152257915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-pfizer-recent-share-price-152257915.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T15:44:00+00:00",
    "headline": "LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs",
    "summary": "Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.",
    "url": "https://finance.yahoo.com/news/llys-glp-1-duo-boosts-154400050.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9c7791b5-0a9e-3a82-93aa-139af9890ca6",
      "content": {
        "id": "9c7791b5-0a9e-3a82-93aa-139af9890ca6",
        "contentType": "STORY",
        "title": "LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs",
        "description": "",
        "summary": "Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.",
        "pubDate": "2025-11-07T15:44:00Z",
        "displayTime": "2025-11-07T15:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/llys-glp-1-duo-boosts-154400050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/llys-glp-1-duo-boosts-154400050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]